Want to see SE:FLUI full AI Analyst Report?
FLUI Stock Chart & Stats
kr10.00
>-kr0.01(-1.38%)
At close: 4:00 PM EST
kr10.00
>-kr0.01(-1.38%)
Day’s Range― - ―
52-Week Rangekr7.65 - kr67.20
Previous CloseN/A
Volume175.18K
Average Volume (3M)16.23K
Market Cap
kr43.55M
Enterprise Valuekr13.95
Total Cash (Recent Filing)kr1.30M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio-59.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr68.60M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Rebound And Positive Gross ProfitA near-doubling of TTM revenue and positive gross profit indicate genuine commercial traction for the product suite. Durable top-line growth combined with positive unit economics gives the company a realistic path to scale fixed costs, improving margin leverage over several quarters if cash allows continued investment.
Conservative Balance Sheet With Zero DebtZero debt reduces refinancing and solvency risk for a small biotech with volatile cash flows. That structural conservatism preserves strategic optionality, limits near-term fixed financial obligations, and improves resilience while the company pursues commercialization and additional funding rounds without immediate debt-servicing pressure.
Focused Microfluidic Platform Addressing Single-cell BiologyA platform addressing single-cell analysis serves growing, structural end markets (drug discovery, cell therapy, disease modeling). Platform and application breadth support recurring consumables, cross-selling and long-term adoption. If differentiated, this niche focus can sustain competitive advantage and durable revenue streams.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flow indicates continued cash burn and limited internal financing capacity. Over a multi-month horizon this forces reliance on external capital, raises dilution risk, restricts investments in sales and R&D, and increases execution risk if financing conditions tighten or milestones slip.
Sustained Unprofitability And Deeply Negative MarginsDespite revenue improvement, deeply negative operating and net margins show the cost base isn't yet aligned with sales scale. Persistent losses imply a longer runway to profitability, potential need for structural cost reductions or pricing changes, and ongoing pressure on returns even as revenue grows.
Small Scale And Dependence On External FundingFluctuating equity and a small operating base constrain the company's ability to expand commercial reach and absorb setbacks. Dependence on additional funding increases dilution risk and can delay strategic initiatives; at small scale, each financing and execution miss has outsized impact on long-term growth prospects.
FLUI FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was kr7.65 and its highest was kr67.20 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is kr43.55M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is Aug 21, 2026 which is in 21 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on May 08, 2026. The company reported kr2.409 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of kr2.409 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 48.444%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in SE:FLUI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.